Xencor Inc (XNCR)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

111 WEST LEMON AVE MONROVIA, CA 91016

Xencor, Inc. develops antibody and protein therapeutics to treat cancer and autoimmune inflammation. The company markets its products to healthcare providers and facilities throughout the United States and internationally.

Data as of 2020-08-09
Market Cap1.84 Billion Shares Outstanding57.243 Million Avg 30-day Volume356.194 Thousand
P/E Ratio Dividend Yield EPS-1.39
Price/Sales26.004 Price cash flow ratio19.3 Price free cash flow ratio-33.2
Book Value9.97 Price to Tangible Book3.22 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.054602
BETA0.863526 52-week High/Low42.28 / 19.35 Stddev0.155398
View SEC Filings from XNCR instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 139 29 (1.9%)
Aggregate 13F shares on 03/31/2020: 51.056 Million 21.899 Million
Aggregate 13F shares on 12/31/2019: 53.27 Million 20.823 Million
Percent change: -4.16% 5.16%
Funds creating new positions: 10 4
Funds Adding to an existing position: 48 11
Funds closing out their position: 28 18
Funds reducing their position: 55 9
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding XNCR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XNCR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SARAN ATUL EVP, CORP DEV, GC & SECRETARY

  • Officer
39,496 2020-08-07 0

GORMAN KEVIN CHARLES CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
438,021 2020-08-05 1

STAFFORD JOHN S III

  • Director
  • 10% Owner
5,000 2020-07-01 5

DAHIYAT BASSIL I

  • Director
0 2020-06-30 1

GUSTAFSON KURT A

  • Director
0 2020-06-25 1

MONTGOMERY ALAN BRUCE

  • Director
0 2020-06-25 1

HATA YUJIRO S

  • Director
0 2020-06-25 1

RANIERI RICHARD J

  • Director
0 2020-06-25 1

FEIGAL ELLEN

  • Director
0 2020-06-25 1

ROSA-BJORKESON DAGMAR

  • Director
0 2020-06-25 3

KUCH JOHN J SR. VICE PRESIDENT & CFO

  • Officer
88,602 2020-06-12 4

RONIN TRADING, LLC

  • 10% Owner
4,621,368 2020-06-04 0

RONIN CAPITAL, LLC

STAFFORD JOHN S III

  • 10% Owner
4,621,368 2020-06-04 0

CARTER BRUCE L A

2,000 2020-05-18 0

DESJARLAIS JOHN R SR. V.P., RESEARCH & CSO

  • Officer
92,953 2020-03-02 3

ECKERT CELIA VP, GENERAL COUNSEL AND SECY

  • Officer
3,147 2020-03-02 2

ROWLAND LLOYD A GENERAL COUNSEL

  • Officer
0 2020-02-14 0

YANG ALLEN SVP, CHIEF MEDICAL OFFICER

  • Officer
31,900 2019-12-16 2

BARACCHINI EDGARDO JR

  • Director
0 2019-11-25 0

FOSTER PAUL A CHIEF MEDICAL OFFICER

  • Officer
0 2019-02-12 0

STAFFORD JOHN S JR

  • Director
346,671 2019-01-02 0

WERNER HAROLD R

  • 10% Owner
0 2018-07-30 0

BALTERA ROBERT JR.

  • Director
0 2018-07-26 0

FLEMING JONATHAN

  • Director
0 2015-06-09 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

GORMAN KEVIN CHARLES - Director

2020-06-25 A 13,953 a 13,953 0.00 direct

HATA YUJIRO S - Director

2020-06-25 A 13,953 a 13,953 0.00 direct

GUSTAFSON KURT A - Director

2020-06-25 A 13,953 a 13,953 0.00 direct

FEIGAL ELLEN - Director

2020-06-25 A 13,953 a 13,953 0.00 direct

ROSA-BJORKESON DAGMAR - Director

2020-06-25 A 13,953 a 13,953 0.00 direct

MONTGOMERY ALAN BRUCE - Director

2020-06-25 A 13,953 a 13,953 0.00 direct

RANIERI RICHARD J - Director

2020-06-25 A 13,953 a 13,953 0.00 direct

KUCH JOHN J - Officer SR. VICE PRESIDENT & CFO

2020-06-15 G 2,000 d 88,602 88,602.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments